Trial Profile
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Ewing's sarcoma; Osteosarcoma
- Focus Therapeutic Use
- Acronyms CABONE
- 17 Feb 2020 Primary endpoint has been met. (Objective response)
- 17 Feb 2020 Primary endpoint has been met. (Objective response)
- 17 Feb 2020 Primary endpoint has been met. (Non-progression)